Details for New Drug Application (NDA): 050519
✉ Email this page to a colleague
NDA 050519 describes NEBCIN, which is a drug marketed by Lilly and is included in four NDAs. Additional details are available on the NEBCIN profile page.
The generic ingredient in NEBCIN is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
The generic ingredient in NEBCIN is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
Summary for 050519
| Tradename: | NEBCIN |
| Applicant: | Lilly |
| Ingredient: | tobramycin sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1.2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
